Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Quemliclustat · AB-680

Small molecule · Inhibitor of CD73 (NT5E) · developed by Arcus Biosciences

Phase 2 Most advanced trial
1 Registered trials

What is Quemliclustat?

Quemliclustat is a small molecule inhibitor of CD73, an ectoenzyme that converts adenosine monophosphate to adenosine in the tumor microenvironment. By blocking CD73, it reduces adenosine-mediated immune suppression and enhances CD8+ T cell and NK cell activity. It is studied in gastrointestinal tract malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AB-680
Drug type
Small molecule
Targets
CD73 (NT5E)
Mechanism
Inhibitor of CD73 (NT5E)
Pathways
adenosine signaling, immune activation, CD8+ T cell response, NK cell activation
Therapy area
Oncology
Developer
Arcus Biosciences, Inc.
In trials of
GILD
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
J6K8WSV73A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05329766 Phase 2 Gastrointestinal Tract Malignancies Active not recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastrointestinal Tract Malignancies

Other drugs acting on NT5E

Dalutrafusp Alfa Phase 2 ORIC-533 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.